ConFlow MedTech is unremittingly dedicated to advancing cardiovascular medical device innovation, with a strong focus on R&D, production, and industrial operations. Our commitment lies in leveraging cutting-edge high-tech solutions through independent R&D and clinical application to establish ourselves as a prominent global innovator in medical product manufacturing. Our management team at ConFlow MedTech has extensive experience in the field of structural heart disease, with over a decade of involvement. We collaborate closely with a team of professional experts in project R&D, clinical quality registration, and market sales. Our company boasts a portfolio of more than 20 international PCT, invention, and utility model patents.

Nestled in the heart of Songjiang Science and Technology City, Shanghai Lingang Group proudly occupies a spacious 2,200-square-meter complex. This facility boasts a pristine environment featuring a 10k Grade clean workshop, well-equipped laboratories, a machining platform, and modern office spaces. Beyond our ongoing clinical trial work on the research diverter project, ConFlow MedTech is actively engaged in animal experimental research for innovative heart intervention and valve products. Our mission is to create a distinctive and innovative platform for R&D in the field of structural heart disease.

The FreeFlow® percutaneous atrial septal shunt system has successfully undergone multiple clinical trials, leading to significant breakthroughs in clinical symptoms and heart function among postoperative heart failure patients. Its clinical efficacy stands out, offering a novel treatment option for heart failure patients beyond conventional drug therapy. This cutting-edge system, FreeFlow®, is the first of its kind in Mainland China, featuring rapid endothelialization of its polymer membrane and secondary recycling capabilities within the atrial septum. Its unique elliptical design reduces implant volume and allows compatibility with a smaller delivery system. This pioneering technology has secured multiple patents and boasts complete independent intellectual property rights, firmly establishing it as a homegrown Chinese research achievement.

Ms. Chen Xiumin, the visionary founder of ConFlow MedTech, suggests that China's innovative cardiovascular medical sector is entering a period of fats track following a decade of dedeicated and strenuous exploration and accumulation. National and local authorities have introduced numerous policies and incentives to stimulate medical technology transformation and foster independent R&D of innovative medical devices. With rich clinical experience, Chinese medical practitioners have ingeniously devised multiple treatment plans and patented technologies, addressing various clinical challenges and engineering design concepts. Chinese R&D engineers, equipped with practical experience in domestic and international innovative product development, demonstrate expertise across the entire spectrum of technology and product development within research and development projects. Chinese suppliers have swiftly enhanced their raw materials, processing techniques, supporting equipment, and quality standards through ongoing collaboration with major manufacturers from home and abroad. Underpinning these advancements is the push for bulk medical consumables procurement, further driving exploration of high-quality original research and innovation projects in the Chinese capital market.

In this transformative era of technological innovation, ConFlow MedTech, a China-based cardiovascular innovative medical device company with a global perspective, is capitalizing on this opportune moment. With a pragmatic and innovative approach, a professional R&D team, and years of experience in clinical transformation, ConFlow MedTech is poised to secure its position and achieve even greater milestones in the future.

Dr. Ji Tianrong, founder of TigerYeah Investment, highlighted the huge population of structural heart disease patients in Mainland China, coupled with unmet clinical demands. At present, the field of structural heart disease medical devices market is booming, offering various innovative avenues and substantial potential for diversification. Among the plethora of start-ups, ConFlow MedTech stands out for its ability to seamlessly collaborate with exceptional clinical experts, resulting in a range of impressive and mature innovative products. Tai Yu prioritizes investments in medical devices, particularly in cardiovascular intervention therapy. We anticipate that partnering with ConFlow MedTech will expedite product launches, allowing it to promptly serve a substantial number of patients with structural heart disease.

The Head of the Taikun Fund project emphasized that cardiovascular disease remains a pivotal focus of innovative device R&D. As China's aging population accelerates, the prevalence of cardiovascular diseases continues to climb, creating a substantial gap in clinical needs. ConFlow MedTech, led by an experienced industry team, has responsively established a comprehensive R&D pipeline through independent research and technology transfer. Their flagship product, FreeFlow®, has exhibited significant clinical efficacy and a smooth development trajectory. As investors in this round, we will closely monitor ConFlow MedTech's progress and requirements, actively support the development of various innovative products, and contribute to its emergence as a leading player in the cardiovascular innovation device sector.